A phase I trial of recombinant gamma interferon in patients with cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00205575PMID 3933818PMCID PMC11038644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer.

  1984cited by this paper
• Potentiating effect of murine interferon-γ-containing lymphokine preparations on the antiviral and antiproliferative effects of murine interferon-α/β: identification of the potentiation factor as murine interferon-γ itself

  1984cited by this paper
• Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons

  1984cited by this paper
• Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome.

  1984cited by this paper
• Pharmacokinetic study of partially pure gamma-interferon in cancer patients.

  1984cited by this paper
• Alpha interferon for induction of remission in hairy-cell leukemia.

  1984cited by this paper
• Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.

  1984cited by this paper
• Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.

  1984cited by this paper
• Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.

  1984cited by this paper
• Potentiating effect of murine interferon-gamma-containing lymphokine preparations on the antiviral and antiproliferative effects of murine interferon-alpha/beta: identification of the potentiation factor as murine interferon-gamma itself.

  1984cited by this paper
• Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.

  1984cited by this paper
• Renal cell carcinoma: antitumor effects of leukocyte interferon.

  1983cited by this paper
• Functional identity between murine γ Interferon and macrophage activating factor

  1983cited by this paper
• Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

  1983cited by this paper
• Recombinant interferon-gamma increases HLA-DR synthesis and expression.

  1983cited by this paper
• Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial.

  1983cited by this paper
• Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

  1983cited by this paper
• Functional identity between murine gamma interferon and macrophage activating factor.

  1983cited by this paper
• Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma.

  1983cited by this paper
• Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes.

  1983cited by this paper
• Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.

  1982cited by this paper
• A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.

  1982cited by this paper
• Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients.

  1982cited by this paper
• Structure of the human immune interferon gene

  1982cited by this paper
• Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

  1981cited by this paper
• Evidence that types I and II interferons have different receptors

  1981cited by this paper
• Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.

  1980cited by this paper
• Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.

  1980cited by this paper
• Increased monocyte‐mediated cytostasis of lymphoid cell lines in breast and lung cancer patients

  1979cited by this paper
• Interferon therapy in myelomatosis.

  1979cited by this paper
• Enhanced expression of HLA antigens and β2‐microglobulin on interferon‐treated human lymphoid cells

  1979cited by this paper
• Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

  1978cited by this paper

• Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report

  2025cites this paper
• Optimal therapy schedule of chimeric antigen receptor (CAR) T cell immunotherapy.

  2025cites this paper
• The Association of RNase L, Cytokines, and Chemokines With Severity of Multisystem Inflammatory Syndrome in Children

  2025cites this paper
• Optimising Chemotherapy for Advanced High-Grade Serous Ovarian Cancer via Delay-Differential Equations

  2025cites this paper
• A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers

  2024influential citation
• Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy

  2024cites this paper
• Engineering interferons and interleukins for cancer immunotherapy.

  2022cites this paper
• A Computational Platform Integrating a Mechanistic Model of Crohn’s Disease for Predicting Temporal Progression of Mucosal Damage and Healing

  2022cites this paper
• Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex

  2022cites this paper
• Substratum interactions determine immune response to allogeneic transplants of endothelial cells

  2022cites this paper
• Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans

  2022influential citation
• Targeted delivery of interferon-gamma by synNotch T cells sensitizes neuroblastoma cells to T cell-mediated killing

  2022cites this paper
• Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

  2022cites this paper
• Solar UVR and Variations in Systemic Immune and Inflammation Markers

  2021cites this paper
• Data-Driven Mathematical Model of Osteosarcoma

  2021cites this paper
• Data Driven Mathematical Model of Colon Cancer Progression

  2020cites this paper
• Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy.

  2020cites this paper
• Transient Transfection of the Respiratory Epithelium with Gamma Interferon for Host-Directed Therapy in Pulmonary Tuberculosis

  2020cites this paper
• Challenges and Opportunities to Improve CAR T-Cell Therapy

  2020cites this paper
• Cell-based interferon gene therapy using proliferation-controllable, interferon-releasing mesenchymal stem cells

  2019cites this paper
• Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment

  2019cites this paper
• Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect)

  2019cites this paper
• Anti‐cancer therapy with TNFα and IFNγ: A comprehensive review

  2018cites this paper
• Targeted Delivery of Interferon Gamma Using a Recombinant Fusion Protein of a Fibrin Clot-Binding Peptide With Interferon Gamma for Cancer Gene Therapy.

  2017cites this paper
• Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy

  2016cites this paper
• Prevention of adverse events of interferon γ gene therapy by gene delivery of interferon γ-heparin-binding domain fusion protein in mice

  2014cites this paper
• MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

  2014cites this paper
• Interferon-γ-Induced Necrosis: An Antitumor Biotherapeutic Perspective

  2013cites this paper
• Long-Term Elimination of Hepatitis C Virus from Human Hepatocyte Chimeric Mice After Interferon-γ Gene Transfer

  2013cites this paper
• in Mice -Interferon γ Clearance and Distribution of Recombinant Murine

  2013cites this paper
• [Control of spatiotemporal distribution of interferon γ by genetically fusing functional peptides].

  2012cites this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cites this paper
• Constant and steady transgene expression of interferon‐γ by optimization of plasmid construct for safe and effective interferon‐γ gene therapy

  2012cites this paper
• Interferon-γ-loaded collagen scaffolds reduce myofibroblast numbers in rat palatal mucosa.

  2011cites this paper
• CHEMOTHERAPY + -IFN (INGARON) OF METASTATIC SKIN MELANOMA. CLINICAL AND IMMUNOLOGICAL STUDY

  2009cites this paper
• Targeted Delivery of Murine IFN-γ Using a Recombinant Fowlpox Virus: NK Cell Recruitment to Regional Lymph Nodes and Priming of Tumor-Specific Host Immunity

  2008cites this paper
• Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ

  2008cites this paper
• Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma--preclinical studies.

  2006cites this paper
• Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis.

  2006cites this paper
• Nasopharyngeal Cervical cancer Hematological malignancies Hairy cell leukemia * Non-Hodgkin ' s lymphoma Low grade Intermediate and high grade Hodgkin ' s disease Cutaneous T-cell lymphoma Chronic lymphocytic leukemia Multiple myeloma Chronic myelogenous leukemia

  2006cites this paper
• Ineffective Treatment of Keloids with Interferon Alpha-2b

  2006cites this paper
• Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor α and interferon γ in cell lines derived from gynecological malignancies

  2005cites this paper
• Antitumor from Counterregulatory Mechanisms to Tumor Vessels Uncouples γ Targeted Delivery of IFN

  2005cites this paper
• Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.

  2005cites this paper
• Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon γ

  2005cites this paper
• Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay

  2004cites this paper
• Title Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma : a Southwest Oncology Group study

  2004cites this paper
• Title Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma : A Southwest Oncology Group Study-Response Permalink

  2004cites this paper
• Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects

  2004cites this paper
• A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours

  2004cites this paper
• Interferon-gamma therapy: evaluation of routes of administration and delivery systems.

  2002cites this paper
• CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

  2002cites this paper
• Interferon‐γ therapy: Evaluation of routes of administration and delivery systems

  2002cites this paper
• Interferon γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis

  2001cites this paper
• Avian cytokines - the natural approach to therapeutics.

  2000cites this paper
• The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.

  1998cites this paper
• CA 125 is dominantly expressed by arrest of G0/G1 phase in uterine cervical adenocarcinoma cell line.

  1998cites this paper
• Inhibition of human mast cell growth and differentiation by interferon gamma-1b.

  1998cites this paper
• Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

  1997cites this paper
• Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

  1995cites this paper
• Fc Receptors Expression and Function in Mononuclear Phagocytes from AIDS Patients: Modulation by IFN‐Gamma

  1994cites this paper
• Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.

  1994cites this paper
• Interferon-gamma: a key immunoregulatory lymphokine.

  1993cites this paper
• Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.

  1993cites this paper
• Antitumor response to recombinant murine interferon γ correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages

  1993influential citation
• A Southwest Oncology Group Phase I Study of the Sequential Combination of Recombinant Interferon-γ and Recombinant Interleukin‐2 in Patients with Cancer

  1992cites this paper
• Interleukin‐2 in Association with Increasing Doses of Interferon‐Gamma in Patients with Advanced Cancer

  1992cites this paper
• Effect of interferon-gamma on B lymphocytes of patients with systemic lupus erythematosus.

  1991cites this paper
• Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor alpha and interferon gamma in cell lines derived from gynecological malignancies.

  1991cites this paper
• Proliferative and antiproliferative effects of interferon‐gamma and tumor necrosis factor‐α on cell lines derived from cervical and ovarian malignancies

  1991cites this paper
• Cardiotoxicity of interferon. A review of 44 cases.

  1991cites this paper
• Alterations in circulating lymphocyte number and function after circulation through colorectal carcinomas.

  1991cites this paper
• Phase I studies of recombinant interferon-gamma.

  1990cites this paper
• Susceptibility of NB‐I Neuroblastoma Cells to Tumoricidal Activity of Monocytes Activated by γ‐Interferon

  1990cites this paper
• Intralesional interferon gamma treatment for keloids and hypertrophic scars.

  1990cites this paper
• Mechanism of interaction between interferon-gamma and antineoplastic agent on the differentiation of HL-60 promyelocytic cells.

  1990cites this paper
• Bone marrow cell modulation and inhibition of myelopoiesis by large granular lymphocytes and natural killer cells.

  1990cites this paper
• Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.

  1990cites this paper
• Recombinant interferon-gamma (rIFN-gamma) in dermatology.

  1990cites this paper
• Expression of a resistance mechanism in ovarian and cervical carcinoma cells prevents their lysis by gamma-interferon.

  1990cites this paper
• In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.

  1990cites this paper
• Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes.

  1990cites this paper
• Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors.

  1990cites this paper
• Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study.

  1989cites this paper
• Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

  1989cites this paper
• Induced Proteins in Human Peripheral Mononuclear Cells Over a Range of Clinically Tolerable Doses of Interferon-γ

  1989cites this paper
• Interferons modulate the expression of hormone receptors on the surface of murine melanoma cells.

  1989cites this paper
• Biological response modifiers: the new immunotherapy.

  1989cites this paper
• Enhancement of primary and secondary immune responses by interferon-gamma.

  1989cites this paper
• Inhibition of proliferation of lines derived from human cervical carcinomas by cytotoxic drugs and by recombinant interferons.

  1989cites this paper
• pH dependence of the reversible and irreversible thermal denaturation of gamma interferons.

  1989cites this paper
• A phase I trial of recombinant human interferon-γ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS)

  1989cites this paper
• Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma.

  1989cites this paper
• Clearance and distribution of recombinant murine gamma-interferon in mice.

  1988cites this paper
• Ex vivo activation of killer monocytes (AKM) and their application to the treatment of human cancer

  1988cites this paper
• Enhancement of a secondary antibody response to vesicular stomatitis virus "G" protein by IFN-gamma treatment at primary immunization.

  1988cites this paper
• A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma.

  1988cites this paper
• Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease

  1988cites this paper
• The treatment of cancer with activated cytotoxic leukocyte subsets.

  1988cites this paper
• The determination of an immunologically active dose of interferon-gamma in patients with melanoma.

  1988cites this paper